SCHEMBL716917

SCHEMBL716917

CCOC(=O)CCN(C)C(=O)c1ccc(NC(c2oc3ccc(-c4cccnc4OC)cc3c2C)C(C)C)cc1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
FFAR4 Q5NUL3 2/20 0.34
KMT2A Q03164 1/20 0.33
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
KLKB1 P03952 1/20 0.32
GCG P01275 1/20 0.31
ABL1 P00519 1/20 0.30
GSK3B P49841 1/20 0.30
SOS1 Q07889 1/20 0.30
NAMPT P43490 2/20 0.30
HIF1A Q16665 1/20 0.30
BTK Q06187 1/20 0.30
DHODH Q02127 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL718053 0.93 FFAR4 (0.40) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL718031 0.87 PTGS2 (0.37) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL720184 0.85 BTK (0.42) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL13069674 0.85 FFAR4 (0.34) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL717838 0.82 HIF1A (0.37) KMT2ARAB9AHIF1A
SCHEMBL721739 0.81 NPC1 (0.40) KMT2ANPC1RAB9A
SCHEMBL719948 0.80 CASP3 (0.41) NPC1RAB9A
SCHEMBL720474 0.80 PTGS2 (0.43) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL721410 0.79 KMT2A (0.33) KMT2ANAMPT
SCHEMBL719544 0.79 CASP3 (0.40) KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP HDAC3 135/4885HDAC1 91/4885HDAC2 324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.